LETO, SIMONETTA MARIA

LETO, SIMONETTA MARIA  

Mostra records
Risultati 1 - 6 di 6 (tempo di esecuzione: 0.008 secondi).
Titolo Data di pubblicazione Autore(i) File
Effective drug combinations in breast, colon and pancreatic cancer cells 2022 Jaaks P.; Coker E.A.; Vis D.J.; Edwards O.; Carpenter E.F.; Leto S.M.; Dwane L.; Sassi F.; Lightfoot H.; Barthorpe S.; van der Meer D.; Yang W.; Beck A.; Mironenko T.; Hall C.; Hall J.; Mali I.; Richardson L.; Tolley C.; Morris J.; Thomas F.; Lleshi E.; Aben N.; Benes C.H.; Bertotti A.; Trusolino L.; Wessels L.; Garnett M.J.
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment 2015 Kavuri, Shyam M; Jain, Naveen; Galimi, Francesco; Cottino, Francesca; Leto, Simonetta M; Migliardi, Giorgia; Searleman, Adam C; Shen, Wei; Monsey, John; Trusolino, Livio; Jacobs, Samuel A; Bertotti, Andrea*; Bose, Ron* (*Corresponding Authors)
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. 2015 Zanella ER;Galimi F;Sassi F;Migliardi G;Cottino F;Leto SM;Lupo B;Erriquez J;Isella C;Comoglio PM;Medico E;Tejpar S;Budinsk E;Trusolino L*;Bertotti A*(*Co-Senior e Corresponding Authors)
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. 2014 Leto SM;Trusolino L
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders 2018 Andrea Marcinnò; Fabiana Marnetto; Paola Valentino; Serena Martire; Alessia Balbo; Aurora Drago; Maria Leto; Marco Capobianco; Giancarlo Panzica; Antonio Bertolotto
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas 2015 Leto, Simonetta M.; Sassi, Francesco; Catalano, Irene; Torri, Valter; Migliardi, Giorgia; Zanella, Eugenia R.; Throsby, Mark; Bertotti, Andrea; Trusolino, Livio